These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19721011)

  • 1. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease.
    Beyersdorf N; Ding X; Hünig T; Kerkau T
    Blood; 2009 Nov; 114(20):4575-82. PubMed ID: 19721011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro polyclonal activation of conventional T cells with a CD28 superagonist protects mice from acute graft versus host disease.
    Beyersdorf N; Werner S; Wolf N; Hünig T; Kerkau T
    Eur J Immunol; 2015 Jul; 45(7):1997-2007. PubMed ID: 25907100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. During acute graft versus host disease CD28 deletion in donor CD8
    Uri A; Lühder F; Kerkau T; Beyersdorf N
    Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD.
    Ermann J; Hoffmann P; Edinger M; Dutt S; Blankenberg FG; Higgins JP; Negrin RS; Fathman CG; Strober S
    Blood; 2005 Mar; 105(5):2220-6. PubMed ID: 15546950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody.
    Beyersdorf N; Ding X; Blank G; Dennehy KM; Kerkau T; Hünig T
    Blood; 2008 Nov; 112(10):4328-36. PubMed ID: 18780833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
    J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Hoffmann P; Ermann J; Edinger M; Fathman CG; Strober S
    J Exp Med; 2002 Aug; 196(3):389-99. PubMed ID: 12163567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.
    Holler A; Zech M; Ghorashian S; Pike R; Hotblack A; Veliça P; Xue SA; Chakraverty R; Morris EC; Stauss HJ
    Haematologica; 2016 Apr; 101(4):482-90. PubMed ID: 26802053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute graft-versus-host disease without costimulation via CD28.
    Speiser DE; Bachmann MF; Shahinian A; Mak TW; Ohashi PS
    Transplantation; 1997 Apr; 63(7):1042-4. PubMed ID: 9112366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent control of acute graft-versus-host disease lethality after immunization with a novel DNA vaccine targeted to B7-1/CD28 costimulatory signaling pathway.
    Luo Y; Liang F; Liu N; Xue H; Song X; Yuan F; Long J; Zhao X; Sun Y; Xi Y
    J Immunother; 2013 Feb; 36(2):82-92. PubMed ID: 23377669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD28-specific antibody prevents graft-versus-host disease in mice.
    Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
    J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.
    Li M; Sun K; Redelman D; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):739-50. PubMed ID: 20338256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
    Zeng M; Guinet E; Nouri-Shirazi M
    Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy.
    Mesel-Lemoine M; Cherai M; Le Gouvello S; Guillot M; Leclercq V; Klatzmann D; Thomas-Vaslin V; Lemoine FM
    Blood; 2006 Jan; 107(1):381-8. PubMed ID: 16160005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.
    Trenado A; Sudres M; Tang Q; Maury S; Charlotte F; Grégoire S; Bonyhadi M; Klatzmann D; Salomon BL; Cohen JL
    J Immunol; 2006 Jan; 176(2):1266-73. PubMed ID: 16394018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.